Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Luminex and Mayo Clinic have signed a development licensing agreement that enables Mayo to provide genetic and other testing services to patients using Luminex's xMAP technology. The agreement contains collaboration and licensing provisions for thalassemia and also provides opportunities for additional test content creation.
Subscribe to our email newsletter
Mayo Clinic will enhance its current genetic testing services for thalassemia to include a new molecular diagnostic test based on multiplex ligation-dependent probe amplification (MLPA) and bead-based liquid micro-array technology using xMAP technology from Luminex.
The new technology is said to help in reducing turnaround time of test results from 7-10 days to 2-3 days and also eliminates the need for radioactive elements in the test.
Patrick Balthrop, president and CEO of Luminex, said: “We are thrilled to collaborate with Mayo to develop new genetic testing services for thalassemia and look forward to supporting additional ways our xMAP technology can be used to enhance the diagnosis and treatment of patients with other conditions.”